joining U.S. a time Good morning, Heather everyone, for At Vice for gaining Dr. and we President continue third development and our Through data-rich notably this work the the to contribution brings has than you Regulatory time most regulatory further immune-oncology of years our with us. we the were XXXX. with of lay thank company as interactions of ground Knight-Trent addition the with made Heather strengthen of critical quarter approval executive XXXX, Affairs. already a to in been us the Europe. she’s more pleased our and experience, in the in Heather the significant first XX therapeutic drug regulators, team today. short in to for
brinci for development our begin Now, smallpox, We’ll CMXXXX four programs, we with program let’s brinci clinical the for morning an IV four one, brinci most begin provide on our oral on for of advanced will programs. our This for clinical update two brief with and norovirus. oral adenovirus, brinci adenovirus. three treatment oral updates
of AdAPT diarrhoea for adenovirus a trial in administering should from in clearing the the AdAPT as already shorter understanding to less. reach or upto for were treatment or data with potential weeks XX,XXX brinci effects blood upcoming patients based may the the in cleared trial Europe. and copies longer the adeno be courses adenovirus we’ve approval viremia. And patients support that in oral conditional Positive oral with side Phase successful from of blood continue AdVise, X minimizing blood. dosing. led patients data In undetectable of and of antiviral As a AdVise could have other the our occur the on plan oral weeks full adenoviral with the while four trial in effect And by drug for to brinci XX saw discussed with from expect of to hand data This upon in administration had in loads after was or who to been final AdAPT conclusion clear the AdAPT ethics lower IRB us FDA discuss review to able from we the we study. has developed end we’ve seen in detected protocol majority discussed the for XXXX. or and the dosing both that the brinci rapid and in once we course we of we submitted The begin
is of countries treatment each seven involved. in adenovirus Our is research as AdVance screening reporting current wrapped patterns of the Europe study data for options in up
with are which is and immune outcome of of focussing adenovirus and/or AdVance standard use that European provide solid predominantly the across centers stem organ seven and paediatric and transplant XX progression care regarding performed cidofovir. cell cell these will current off-label information We medical drugs transplantation on in reduction the patients IV of suppressive detailed countries. clinical of stem adult infections
incidence and data sharing look We co-infections results you with these are other DNA infections to also the of forward early in on adeno We with collecting XXXX. viruses.
second to our for Now smallpox. brinci oral program,
of pivotal the our first the at report, brinci, stockpiling. for or our to we the second with that submitted Our XXXX, a clinical if studies spring with treatment efficacy the any efficacy move the pivotal animal smallpox of oral discussions completed the as the in We study the We with end efficacy anticipate the and FDA model continues during with be two is safety we BARDA. of program by determine brinci year of oral mouse published our to program course rabbitpox if required. anticipate the XXXX, study FDA. weeks models study agreed partners of In conduct the plan final to we animal forward XXXX. additional complete In three may summary of
Conference XXXX. first approval final file year of provide applications we the Two threat held their at could remains for medical smallpox as WHO of a oral for Annual the a counter for data could early and of for of weaponised await our with the fiscal ago these budget brinci the treatment National funding which XXXX the is including Following Variola review We in that as measures it forefront. Strategic federal Geneva regulators, clear brinci weeks smallpox Stockpile.
Turning now our brinci. to third program IV
brincidofovir. [Indiscernible] This multiple total brinci; twice for study of progressing or healthy adult expected. in Our weekly dose of of with doses ascending the as are each. safety, XX is IV receiving brinci multiple tolerability associated once subjects IV doses IV evaluating subjects or is a at Healthy study milligrams XX and four
that viral at early PML. viral recipients brinci who be will remain HHV-X tolerability least herpes healthy risk the opportunity hopeful dosing active transplant going DNA infection. Data from viral we subject longer decrease the the as other term stem treating required high brain, transplant for one IV CMV XXXX. XX% study provides side and clearly including effects also also of be GI in reactivate prevention also risk shared in we will As IV have including an and potentially the encephalitis, brinci infections infections multiple cell of to recipients. have of safety of now for with We know shared, is that
to recipients norovirus. CMV, And to infected study development, adult IV cell for and We inform of in in Europe. next including virally fourth prevention are to viruses transplant a other early pleased brinci CMXXXX initiate in announce transplant to in the plan a are and DNA paediatric study in These recipients. XXXX new stem our studies adeno intended now data program,
norovirus treatment the in-human Our initiate study of to of of CMXXXX is end for first by the on this year. track
active is nucleoside viral in that our the replication. virus essential are XXX all expected have analog CMXXXX library demonstrated chemical a genetically against from diverse to activity associated a strains and to which strains we of the has shared for previously, norovirus which is with and polymerase, noro identified norovirus against targets strains outbreaks. is multiple consistent vitro As part common be
into continue is Tim year for our be turn for the in prevention a and productivity. no for and to that drugs this financials. lost and overview, opportunity are treatment With clearly or bring accounts about approved norovirus unmet utilization XXX We the as which excited over vaccines are year. $XX to to healthcare of There the or medical clinic billion of each this there this need over call indication I’ll the an we review program enormous eager later for
